Restatement of results for new reporting structure

RNS Number : 9165A
Croda International PLC
04 June 2021
 

Regulatory News Announcement

4 June 2021

 

Croda International Plc

Restatement of results for new reporting structure

 

Croda International Plc ('Croda' or 'the Group') announced in November 2020 that from 2021 it would amend its reporting structure to report under four sectors - Consumer Care, Life Sciences, Performance Technologies and Industrial Chemicals. 

 

In advance of its half year results on 27 July 2021, the Group is publishing restated segmental results for half year 2020 to provide a like-for-like comparator.

 

Consumer Care comprises the Personal Care sector, including Iberchem, a customer previously reported within Life Sciences, and the Home Care business unit from Performance Technologies.

 

The table below sets out the new structure, showing half year 2020 results as previously reported and the results for the same period restated to reflect the new structure. There is no impact from the Group's acquisitions of Avanti and Iberchem as they were both completed in the second half of 2020.


Sales

Adjusted operating profit*

Half year ended 30 June 2020

Reported currency

 

As

reported

£m

Restated

£m

As

reported

£m

Restated

£m

Consumer Care

226.7

251.1

68.9

73.7

Life Sciences

182.9

179.8

59.4

57.8

Performance Technologies

216.3

195.0

32.7

29.5

Industrial Chemicals

47.0

47.0

  0.6

  0.6

Group

672.9

672.9

161.6

161.6

 

* Adjusted operating profit is stated before exceptional items, acquisition costs and amortisation of intangible assets arising on acquisition. 

 

Further information

 

David Bishop, Director of Investor Relations and Corporate Affairs:    +44 7823 874428

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCEAAKLEENFEFA
UK 100

Latest directors dealings